George Culmer
Analyst · Nomura. Please, go ahead
Okay, alright. Chintan. Going back to the first question on SVR, and attrition rates and composition, all those sorts of things, to be very precise about it, the SVR book in totality, at the end of Q1, stood at about £163 billion. And within that, the Halifax book was £56 billion, that's a 399 book. We've got the Lloyds book especially about 260 that stood at £43 billion. BOS book this is about 396 in terms of rate, that stood at £12 billion. And I think Birmingham Midshires, which face about 294 that stood at £37 billion. And I think we’ve got about another £15 billion, if my math is correct, which gets you back to the total. So that's the book, of which the Halifax, at 399, is just on £56 billion. That £56 billion compares to – at the yearend, that was about £57 billion and this time last year was about £59 million. So you are looking at attrition of sort of 5%, 6%, 7% in that. Quite interestingly, the Lloyds book, that £43 billion, that was sort of £44 billion at Q4 and by £48 billion at Q1 this time last year. And actually on the Birmingham Midshires, using the same timeframe, £37 billion, £38 billion, £39 billion. So I think as we see – that we’ve seen attrition around about the sort of 5%, 6%, 7%. And that's kind of been across all books, irrespective of price. And we've seen a continuation of that as we've moved into the first quarter. So that's what we're seeing, and that's what we would expect to see as we continue to move forward throughout 2015. That's been our experience, and that remains our experience. That's the cut on the SVR book. Second question on the PPI, there isn't a go-to rate. We've disclosed that number in terms of those whom we've contacted, paid out on, et cetera, since 2000, and that's some 45%. So there is no go-to number. You’re absolutely right; it's not going to go to 100%. The best evidence I can give you of that, when we do these past book reviews and one does proactive mailings, and these are very explicit proactive mailings and you've got to mail people up to three times who had a PPI policy, the response rate is about 30%, or just under that. So even though where there's clear evidence of had a policy, as I say, you have about a 30% response rate, so it’s not going to go to 100%. I can't tell you whether it's 48%, 50%, or whatever. What I can tell you on PPI, as we've disclosed, I think, in RNS [ph], obviously, made no provision at Q1. What we're seeing on the three elements, you've got the past book review, you've got remediation on the reactives on the past book review. And the remediation, we've previously said that we expect to be complete basically first half of this year. That very much remains the case, so we would complete those. Because we're going through those, the monthly spend has gone up. I think we've spent, cash spend about £800 million in this quarter. The norm would be about £600 million. But what that reflects, effectively, that's good news because that represents us clearing cases and getting through that remediation. Hopefully, we will be through that in the first half. Reactives, again, as we say in the RNS, I think we're about 11% down Q1 on Q1 slightly up on Q4, but part of that is seasonality. Does still remain uncertain and risk does still remain, I should point that out. And we did disclose that Q4; that, were reactives to remain flat, there would be this, approximately, £700 million charge at the half-year, of that order. That risk still remains. At the moment, we've got about £1.7 billion, I think, left unutilized on the balance sheet. And, as I said, we've taken no action at Q1. Making good progress on the first two elements, but there is still risk attaching with regard the reactives. Although, obviously, once you're through the first two and just into the reactives, PPI, it moves down to a different scale of issue in terms of – a different scale of financial outlay. But that risk, that’ still remain.